Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are frequently discontinued in patients with chronic kidney disease (CKD). Documented adverse drug reactions (ADRs) in medical records may provide insight into the reasons for treatment discontinuation.
Methods: In this retrospective cohort of US veterans from 2005 to 2019, we identified individuals with CKD and a current prescription for an ACEi or ARB (current user group) or a discontinued prescription within the preceding 5 years (discontinued group). Documented ADRs in structured datasets associated with an ACEi or ARB were categorized into 17 pre-specified groups. Logistic regression assessed associations of documented ADRs with treatment discontinuation.
Results: There were 882,441 (73.0%) individuals in the current user group and 326,794 (27.0%) in the discontinued group. There were 26,434 documented ADRs, with at least one documented ADR in 7,520 (0.9%) current users and 9,569 (2.9%) of the discontinued group. ADR presence was associated with treatment discontinuation, aOR 4.16 (95% CI: 4.03, 4.29). The most common documented ADRs were cough (37.3%), angioedema (14.2%), and allergic reaction (10.4%). ADRs related to angioedema (aOR 3.81, 95% CI: 3.47, 4.17), hyperkalemia (aOR 2.03, 95% CI: 1.84, 2.24), peripheral edema (aOR 1.53, 95% CI: 1.33, 1.77), or acute kidney injury (aOR 1.32, 95% CI: 1.15, 1.51) were associated with treatment discontinuation.
Conclusion: ADRs leading to drug discontinuation were infrequently documented. ADR types were differentially associated with treatment discontinuation. An understanding of which ADRs lead to treatment discontinuation provides an opportunity to address them at a healthcare system level.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424561 | PMC |
| http://dx.doi.org/10.1159/000530988 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcranial Pulse Stimulation in Alzheimer's: Long-Term Feasibility and a Multifocal Treatment Approach.
Brain Sci
August 2025
Department for Neurology and Neurorehabilitation, Hospital zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, 47906 Kempen, Germany.
Background/objectives: Neuromodulation is under investigation as a possibly effective add-on therapy in Alzheimer's disease (AD). While transcranial pulse stimulation (TPS) has shown positive short-term effects, long-term effects have not yet been fully explored. This study aims to evaluate the long-term feasibility, safety, and potential cognitive benefits of TPS over one year in patients with Alzheimer's disease, focusing on domains such as memory, speech, orientation, visuo-construction, and depressive symptoms.
View Article and Find Full Text PDFAdverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.
BMC Cancer
August 2025
Department of Interventional Radiology, Zhenjiang First People's Hospital, No.8 of Dianli Road, Zhenjiang City, 212000, Jiangsu Province, China.
Objective: This study sought to comprehensively evaluate the safety profile of tremelimumab and durvalumab in patients with hepatocellular carcinoma (HCC) by examining adverse drug reaction (ADR) documented in the Food and Drug Administration's Adverse Event Reporting System (FAERS) database.
Methods: Data from the FAERS database spanning from the first quarter of 2004 to the first quarter of 2025 were extracted, filtered, and standardized. The Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) method were utilized to analyze the signal strength and identify potential ADRs.
Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles.
Sci Rep
August 2025
Department of Pharmacy, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine (Taicang Hospital of Traditional Chinese Medicine), Taicang, China.
Viloxazine and dextroamphetamine as newly approved drugs for the medical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in recent years give new options for the treating of related disorders, including anxiety, and depression. In our research, we conducted an assessment of adverse drug reactions (ADRs) associated with the utilization of these two medications, as documented in the database. By analyzing the adverse drug reaction profiles and combining them with relevant reviews, we aim to help select the drug with the least risk to meet the specific needs of different patients.
View Article and Find Full Text PDFA critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form).
J Basic Clin Physiol Pharmacol
July 2025
Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, India.
Objectives: This study will identify strengths and weaknesses of ADR reporting forms of study countries.
Methods: This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries.
Objective: To comprehensively analyze worldwide safety data of gadoxetate disodium after 20 years of use and to review its reclassification from group III to group II on the American College of Radiology (ACR) nephrogenic systemic fibrosis (NSF)-risk classification scheme.
Materials And Methods: Two safety data sets were analyzed: 23 clinical phase I to IV studies and Bayer pharmacovigilance database (PV) from 2004 to 2024. In addition, a literature review on NSF reports with special focus on patients with different degrees of renal impairment was performed.